1 / 1

TRANSFER-AMI

TRANSFER-AMI. Primary endpoint: death, MI, HF, severe recurrent ischemia, or shock 11.0% in pharmacoinvasive arm vs. 17.2% in standard treatment arm Reinfarction: 3.4% vs. 5.7% (p = 0.06) Recurrent ischemia: 0.2% vs. 2.1% (p = 0.003). (p = 0.004). (p = 0.39). Pharmacoinvasive arm (n = 537).

janna
Download Presentation

TRANSFER-AMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TRANSFER-AMI Primary endpoint: death, MI, HF, severe recurrent ischemia, or shock 11.0% in pharmacoinvasive arm vs. 17.2% in standard treatment arm Reinfarction: 3.4% vs. 5.7% (p = 0.06) Recurrent ischemia: 0.2% vs. 2.1% (p = 0.003) (p = 0.004) (p = 0.39) Pharmacoinvasive arm (n = 537) Standard therapy (n = 522) Trial design:Patients with STEMI who presented to centers where timely primary PCI was not feasible were randomized to a pharmacoinvasive strategy (emergent transfer for PCI within 6 hours of fibrinolysis) or to standard treatment after fibrinolysis. Results 20 4.5 5 17.2 4 3.4 11.0 % 3 10 % 2 Conclusions 1 • Pharmacoinvasive was approach safe and efficacious compared with treatment with thrombolytics and transfer for rescue PCI only • Needs to be distinguished from facilitated PCI • Optimal window based on this and other trials: 2-17 hours 0 0 Primary endpoint Mortality Cantor WJ, et al. N Engl J Med 2009;360:2705-18

More Related